在患有心力衰竭和利尿剂耐药性的患者中,连续直接去除
Veena S Rao1, Juan B Ivey-Miranda1,2, Zachary L Cox3,4
1Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
European journal of heart failure
|April 1, 2024
概括
直接去除 (DSR) 为心力衰竭患者提供了一个有前途的方法. 这种方法涉及腹膜的使用和利尿剂的取消,改善了利尿反应和心脏脏参数,可能提供一种新的治疗方法.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 关键护理医学 关键护理医学
背景情况:
- 循环利尿剂可能会在心力衰竭 (HF) 中恶化心脏脏综合征 (CRS).
- 利尿剂耐药性是管理HF患者的一个重大挑战.
- 直接去除 (DSR) 是一种潜在的替代策略.
研究的目的:
- 为了评估DSR在HF患者的可行性和有效性,有尿素耐药.
- 评估DSR对利尿反应和心脏和脏指标的影响.
- 为了确定DSR是否可以减少对循环利尿剂的依赖.
主要方法:
- 两项前性单臂研究 (红色沙漠和撒哈拉) 招募了需要高剂量循环利尿剂的HF患者.
- 循环利尿剂被取消,并使用连续的DSR来实现和维持evolemia.
- 尿液反应通过静脉注射furosemide挑战和尿液量测量来评估.
主要成果:
- 循环利尿药戒断后,DSR显著增加了利尿反应 (81 ± 37 mmol至 223 ± 71 mmol,p < 0.001).
- 患者在1年内维持了DSR的血症,尿剂的重新启动剂量明显低于基线 (基线的中位数为8%).
- 多个功能参数和HF生物标志物显示显著改善 (p < 0.05).
结论:
- 连续的DSR疗法与循环利尿剂的撤销是可行的HF患者与利尿剂耐药性.
- DSR在利尿剂耐药性和心脏小便指标方面表现出实质性和持续性的改善.
- DSR可能代表了对利尿剂耐药性和CRS的新疗法选择,需要在随机对照试验中进一步调查.
更多相关视频
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
23.6K
07:59Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
11.2K
相关概念视频
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:16Antihypertensive Drugs: Action of Diuretics
680
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
680
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
534
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
534
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
624
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
624
01:25Antihypertensive Drugs: Direct Renin Inhibitors
616
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
616